𝔖 Bobbio Scriptorium
✦   LIBER   ✦

α-interferon in hematological malignancies

✍ Scribed by Frank J. Giles; Howard Ozer

Book ID
104361786
Publisher
Elsevier Science
Year
1991
Tongue
English
Weight
381 KB
Volume
2
Category
Article
ISSN
0958-1669

No coin nor oath required. For personal study only.

✦ Synopsis

Recent studies have generated data demonstrating significant clinical activity of a-interferon therapy in each of six hematological malignancies, chronic myeloid leukaemia, essential thrombocythemia, polycythemia rubra vera, non-Hodgkin's lymphomas, multiple myelomatosis and hairy cell leukaemia.

📜 SIMILAR VOLUMES

Pulmonary side effects of interferon-α t
Pulmonary side effects of interferon-α therapy in patients with hematological malignancies
✍ Patrik Anderson; Martin Höglund; Stig Rödjer 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

## Abstract Several side effects of interferon‐α‐2b (IFN‐α) therapy have been described. Pulmonary side effects have seldom been reported. The four patients we describe all developed respiratory disorders while being treated with IFN‐α for hematological malignancies. We point out the similarities a

A phase I trial of α-interferon in combi
A phase I trial of α-interferon in combination with pentostatin in hematologic malignancies
✍ Bernard, Stephen ;Gill, Parkash ;Rosen, Peter ;Gavigan, Molly ;Steagall, Ann ;El 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 721 KB

Pentostatin, a novel inhibitor of adenosine deaminase, has shown activity in various lymphoid malignancies of both the T and B cell lineage. This agent has unique side effects and in general myelosuppression has been mild. Interferon has both antiviral and antineoplastic properties. This agent has s

Molecular genetic biomarkers in hematolo
Molecular genetic biomarkers in hematological malignancies
✍ Adam Bagg; Jeffrey Cossman 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 679 KB

Most hematopoietic malignancies are widely disseminated even in their "early" stages and often do not have a well-defined localized phase. This makes them less amenable to conventional early screening methods such as imaging and observation. Furthermore, the staging systems for lymphomas are not par